by Alicen Baran | Oct 29, 2020 | News, Product Approvals
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥....
by Diana Lebiecki | Jun 15, 2020 | News
The Great Place to Work® Institute has honored Nexus Pharmaceuticals as one of the 2020 Best Workplaces in Chicago. The ranking considered over 27,000 responses from Chicago area employees. Great Place to Work, a global people analytics and consulting firm, evaluated...
by Alicen Baran | Apr 21, 2020 | News, Product Approvals
Lincolnshire, Ill., April 21, 2020 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL...
by Alicen Baran | Feb 26, 2020 | News
Dear Valued Partner: In light of the recent global outbreak of COVID-19 (Novel Coronavirus), Nexus Pharmaceuticals would like to take the opportunity to provide its partners reassurance on Nexus Pharmaceuticals products’ sourcing and manufacturing. The current Nexus...
by Alicen Baran | Nov 19, 2019 | News
Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute. Ninety percent of Nexus employees say the company is a great place to work. The company is proud to employ individuals with a strong work...
by Alicen Baran | Aug 15, 2019 | News
Nexus Pharmaceuticals is pleased to announce the company has ranked #574 in Inc. 5000’s Fastest-Growing Private Companies in America in 2019. Since inception in 2003, and the launch of its first injectable drug in 2017, Nexus Pharmaceuticals has experienced...
